The EMA has now published the following documents adopted in the June meeting of the CVMP:
A draft guideline was adopted for consultation, on user safety of topically administered VMPs (Link).
The latest VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to VMPs was adopted, following the yearly review and update.
A new problem statement was agreed by the CVMP Ad hoc Expert Group on Novel Therapies (ADVENT) on stem cells for veterinary use, regarding specific questions on extraneous agents (Link)
Further documents not yet published will be published on the EMA website in due course.